A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

Yondelis® (trabectedin, ET-743) is a novel marine-derived anticancer compound found in the ascidian Ecteinascidia turbinata. It is currently under phase II/III development in breast cancer, hormone refractory prostate cancer, sarcomas and ovarian cancer. Activity in breast cancer experimental models...

Descripción completa

Detalles Bibliográficos
Autores principales: Zelek, L, Yovine, A, Brain, E, Turpin, F, Taamma, A, Riofrio, M, Spielmann, M, Jimeno, J, Misset, J L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361304/
https://www.ncbi.nlm.nih.gov/pubmed/16736024
http://dx.doi.org/10.1038/sj.bjc.6603142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361304/
https://www.ncbi.nlm.nih.gov/pubmed/16736024
http://dx.doi.org/10.1038/sj.bjc.6603142

Ejemplares similares